Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 3(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04518293Phase 3Completed

Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

Role: lead

NCT04518306Phase 3Completed

Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension

Role: lead

NCT05833958Phase 2Withdrawn

Polypill Versus Metformin in New Onset Type 2 Diabetes

Role: lead

All 3 trials loaded